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ORIGINAL ARTICLE
Background/Aims: Serum levels of highly sensitive C-reactive protein (hsCRP), a vascular inflammatory
marker, may predict the development of cardiovascular disease (CVD) and type 2 diabetes. Women with
polycystic ovary syndrome (PCOS) are at greater risk for type 2 diabetes and CVD. The aim of this study was to
compare hsCRP levels between normal weight women with PCOS and controls with a normal menstrual cycle
and to determine the factors associated with serum hsCRP levels.
Methods: Thirty-nine lean PCOS patients and 24 healthy, regular cycling women were enrolled in this study. We
performed anthropometric measurements, fat computed tomography (CT), and blood sampling to determine
blood chemistry and levels of hsCRP, gonadotropins, testosterone, and sex-hormone binding globulin. We also
conducted 75-g oral glucose-tolerance test and euglycemic hyperinsulinemic clamp to assess insulin sensitivity.
Results: Serum hsCRP concentrations were higher in women with PCOS than in women with regular
mensturation. However, this difference was no longer significant after adjusting for body mass index (BMI).
hsCRP levels were correlated with waist circumference (r=0.46, p<0.01), BMI (r=0.46, p<0.01), visceral fat area
(r=0.45, p<0.01), and systolic (r=0.42, p<0.05) and diastolic blood pressure (r=0.39, p<0.05). hsCRP also tended
to be negatively associated with insulin-mediated glucose uptake (IMGU) (r=-0.31, p=0.07). A multiple regression
analysis revealed that BMI (β=0.29, p<0.05), systolic blood pressure (β=0.39, p<0.01), and IMGU (β=-0.31, p<0.05)
predicted serum hsCRP levels in women with PCOS.
Conclusions: PCOS by itself does not seem to be associated with increased hsCRP levels, whereas known
CVD risk factors affect serum hsCRP levels in PCOS. (Korean J Intern Med 2009;24:350-355)
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INTRODUCTION
Polycystic ovary syndrome (PCOS) is a common endocrine
disorders that affects 5-10% of reproductive-age women
[1,2]. Insulin resistance is considered the most important
pathophysiological factor in PCOS [3-5]. The cellular and
molecular mechanisms of insulin resistance in PCOS have
not yet been elucidated, but they are considered to be
distinct from those of other diseases associated with
insulin resistance [6]. Over half of women with PCOS are
obese [7] and show insulin resistance [8,9]. Therefore,
they have an increased prevalence of hypertension,
diabetes, and cardiovascular disease (CVD) [10,11]. Serum
highly sensitive C-reactive protein (hsCRP), a marker of
chronic subclinical inflammation, is a well-known
predictor for the development of type 2 diabetes and CVD
[12]. It has been reported that serum hsCRP levels
increase in metabolic disorders such as obesity, hyper-
tension, dyslipidemia, and atherosclerosis [12]. A few
studies have examined CRP levels in women with PCOS;Oh JY, et al. Serum C-reactive protein in polycystic ovary syndrome     351
however, the results are not consistent. Some studies
report that CRP levels are increased in women with
PCOS [13-15], supporting the hypothesis that the risk
of diabetes and CVD is increased by chronic inflammation
in PCOS. In contrast, Mohlig et al. [15] reported that
serum CRP levels are associated with obesity rather than
with the presence of PCOS per se. Thus, whether serum
CRP levels are increased in women with PCOS and which
variables predict serum CRP levels remain unclear.
The purpose of this study was to compare hsCRP levels
between lean women with PCOS and women with normal
menstrual cycling, and to investigate the relationship
between serum hsCRP and other CVD risk factors in
women with PCOS. 
METHODS
Subjects 
Thirty-nine lean (body mass index [BMI] <23 kg/m
2)
women with PCOS and 24 regular-cycling control women
were enrolled in this study. The degree of obesity was
classified according to the Asia-Pacific perspective, 2000
[16]. None of the control women had a family history of
diabetes or PCOS. The diagnosis of PCOS was made
according to the National Institute of Child Health and
Human Development (NICHD) criteria [17], i.e., hyper-
androgenism with amenorrhea or oligomenorrhea (less
than nine menstrual cycles per year) and the exclusion of
specific disorders such as adult-onset congenital adrenal
hyperplasia, hyperprolactinemia, and androgen-secreting
neoplasia. Hyperandrogenemia was defined as serum
free testosterone levels greater that the 90th percentile
(>52.2 ng/dL) in women with regular menstrual cycles
and no hirsutism. 
Anthropometric measurements
Height and weight were measured with subjects wearing
lightweight clothing and without shoes. BMI was calculated
as weight (kg)/height (m
2). Waist circumference was
measured on bare skin during mid-respiration at the
narrowest indentation between the 10th rib and the iliac
crest. Blood pressure was measured twice using sphyngo-
manometry following a 10 minute-rest, and mean values
are presented. For the measurement of visceral fat area
(VFA), computed tomography was performed at the
umbilicus level, and fat was defined as pixels within a
window of -144 to -44 Houndsfield units.
Baseline sampling and oral glucose tolerance test
Venous blood sampling was performed to assess
baseline measurements of hsCRP, glucose, lipid, insulin,
testosterone, sex hormone binding globulin (SHBG),
luteinizing hormone (LH), and follicle stimulating
hormone (FSH) following an overnight fast during the
early follicular phase. Blood samples for oral glucose
tolerance tests were obtained at 30 minutes intervals for 2
hours following ingestion of a standard dose of glucose (75
g) to measure glucose and insulin levels.
Glucose clamp technique
Insulin sensitivity was evaluated using a modified
version of hyperinsulinemic euglycemic clamp techniques
described by DeFronzo et al. [18]. A quantitative estimate
of insulin sensitivity, glucose disposal rate, and insulin-
mediated glucose uptake (IMGU) was determined by
recording the mean glucose infusion rate (mg/kg/min) for
the last 15 minutes of a 2-hour hyperinsulinemic euglycemic
clamp.
Assay methods
Analysis of hsCRP was performed using immunoneph-
elometric methods and a BN-II analyzer (Dade Behring,
Deerfield, Germany). The inter- and intra-assay coefficients
of variation were 4.9 and 6.8%, respectively.
Plasma glucose levels were measured using the glucose
oxidase method (Beckman Model Glucos Analyzer 2;
Beckman, Los Angeles, CA, USA). Plasma insulin levels
were determined using a radioimmunoassay (RIA) kit
(Diagnostic Products Corporation [DPC], Los Angeles,
CA, USA). Total cholesterol (TC), HDL cholesterol (HDL-
C), and triglycerides (TG) were measured via enzymatic
methods using a Hitachi 7150 autoanalyzer (Hitachi,
Tokyo, Japan). LDL cholesterol was calculated as TC
(mg/dL) - HDL-C (mg/dL) - TG (mg/dL)/5. Serum
testosterone, SHBG, LH, and FSH were measured
using RIA kits from DPC. Free testosterone levels were
calculated using a formula available on the website of
the International Society for the Study of Aging Male
(http://www.issam.ch/freetestos.htm) based on total
testosterone, SHBG, and albumin values from each
subject [19]. 
Statistical analysis
Data analysis was performed using SPSS version 12.0
(SPSS Inc., Chicago, IL, USA). Data showing a skewed
distribution were logarithmically transformed prior to352 The Korean Journal of Internal Medicine Vol. 24, No. 4, December 2009
statistical analysis. Data are expressed as the mean±
standard deviation, unless otherwise stated. A p value of
<0.05 was considered statistically significant. 
An unpaired t-test was used for comparison of
continuous variables between PCOS and control groups.
A multivariate general linear model was applied for
comparisons between two groups after adjusting for
specific variables. Linear correlations were examined
using Pearson’s correlation. A multiple regression analysis
was performed to determine which variables predict serum
hsCRP levels.
RESULTS
Subject characteristics are summarized in Table 1. Age,
waist circumference, VFA, and systolic and diastolic blood
pressures were not significantly different between PCOS
and control groups. The PCOS group had a higher BMI
(20.8±0.2 vs. 19.9±0.3 kg/m
2, p<0.05); however, BMI in
all subjects was less than 23 kg/m
2. In women with PCOS,
fasting plasma glucose (88±2 vs. 83±2 mg/dL, p<0.05), 2
hour post-load plasma glucose (115±3 vs. 106±3 mg/dL,
p<0.05), 2 hour post-load plasma insulin (36.2±3.4 vs.
19.9±1.5 µU/mL, p<0.05), and free testosterone levels
(1.9±0.6 vs. 2.8±0.4 ng/dL, p<0.05) were higher greater
compared with the control group, and IMGU (5.3±1.4 vs.
6.3±0.3 mg/kg/min, p<0.05) was lower. hsCRP concen-
trations in the PCOS group were higher compared with
the control group (0.72±0.20 vs. 0.27±0.04 mg/L, p<0.05);
however, this difference was not statistically significant
after adjusting for BMI (data not shown). 
hsCRP levels were positively correlated with waist
circumference (r=0.46, p<0.01), BMI (r=0.46, p<0.01),
VFA (r=0.45, p<0.01), systolic (r=0.42, p<0.05) and
diastolic and blood pressure (r=0.39, p<0.05), and tended
to be negatively correlated with IMGU (r=-0.31, p=0.07)
Table 1. Clinical and biochemical characteristics of
the study subjects
Control PCOS
(n=24) (n=39)
Age, yr 26±1 25±1
Waist circumference, cm 66±1 68±1
Body mass index, kg/m
2 19.9±0.3 20.8±0.2*
Visceral fat area, cm
2 33±5 40±3
Systolic blood pressure, mmHg 113±2 114±2
Diastolic blood pressure, mmHg 74±2 75±2
Fasting plasma glucose, mg/dL 83±2 88±2*
Post-load 2 hr glucose, mg/dL 106±3 115±3*
Fasting plasma insulin, µU/mL 5.8±0.8 6.8±0.8
Post-load 2 hr insulin, µU/mL 19.9±1.5 36.2±3.4*
Total-cholesterol, mg/dL 166±3 170±3
Triglycerides, mg/dL 39±6 58±6
HDL-cholesterol, mg/dL 58±3 54±3
IMGU, mg/kg/min 6.3±0.3 5.3±1.4*
Sex hormone binding globulin, nmol/L 56±7 43±4
Free testosterone, ng/dL 0.8±0.5 1.9±0.6*
hsCRP, mg/L  0.27±0.04 0.72±0.20*†
Values are mean±SD.
PCOS, polycystic ovary syndrome; IMGU, insulin mediated glucose
uptake; hsCRP, high sensitivity C-reactive protein.
*p<0.05 vs. control.
†Significance disappeared after adjustment for body mass index.
Table 3. Multiple regression analysis for hsCRP in
women with polycystic ovary syndrome
β SE p value
Body mass index  0.29 0.08 <0.05
Systolic blood pressure  0.39 0.01 <0.01
IMGU -0.31 0.08 <0.05
Fasting plasma insulin  0.13 0.12 0.30
Free testosterone 0.13 0.18 0.34
SE, standard error; hsCRP, high sensitivity C-reactive protein; IMGU,
insulin-mediated glucose uptake. 
Table 2. Correlation between hsCRP and clinical
variables in women with polycystic ovary syndrome
rp value
Body mass index 0.46 <0.01
Waist circumference 0.46 <0.01
Visceral fat area 0.45 <0.01
Systolic blood pressure 0.42 <0.05
Diastolic blood pressure 0.39 <0.05
Fasting plasma glucose -0.10 NS
Post-load 2 hr glucose  0.12 NS
Fasting plasma insulin 0.24 NS
Post-load 2 hr insulin -0.24 NS
Total-cholesterol 0.22 NS
Triglyceride 0.11 NS
HDL-cholesterol -0.09 NS
IMGU -0.31 0.07
Sex hormone binding globulin  -0.12 NS
Free testosterone  0.12 NS
hsCRP, high sensitivity C-reactive protein; NS, not significant; IMGU,
insulin mediated glucose uptake.Oh JY, et al. Serum C-reactive protein in polycystic ovary syndrome     353
in women with PCOS (Table 2).
A multiple regression analysis showed that BMI
(β=0.29, p<0.05), systolic blood pressure (β=0.39,
p<0.01), and IMGU (β=-0.31, p<0.05) predicted serum
hsCRP levels in women with PCOS (Table 3).
DISCUSSION
The purpose of this study was to compare the levels of
hsCRP in lean women with and without PCOS, and
determine whether hsCRP is associated with other CVD
risk factors. The present analysis suggests that PCOS is
not associated with increased CRP levels. In contrast,
documented CVD risk factors appear to predict serum
CRP levels in women with PCOS. In this study, we
recruited only normal-weight women with PCOS to
minimize the effects of obesity on hsCRP levels. 
PCOS is characterized by chronic anovulation, hyper-
insulinemia, hyperandrogenism, and infertility, and it is
one of the most frequently observed endocrine disorders
in reproductive-age women [8]. PCOS shares many
characteristics of metabolic syndrome, including abdominal
obesity, insulin resistance, hypertension, dyslipidemia,
and atherosclerosis [20-22]. Wild et al. [23] reported
that PCOS women have a high prevalence of nonfatal
cerebrovascular disease and cardiovascular risk factors,
including diabetes, hypertension, hypercholesterolemia,
hypertriglyceridemia, and increased waist-to-hip ratio
compared with control women. Furthermore, Elting et al.
[24] recently reported that in women aged 45-54 years
with PCOS, the prevalence of diabetes mellitus is four
times higher and the prevalence of hypertension is 2.5
times higher as compared with control women in the
corresponding age group within a Dutch population. In
contrast, one epidemiologic study did not find any
differences in either all-cause or cardiovascular mortality
in women who had been classified as having PCOS in the
past [25]. 
It has been reported that surrogate markers of cardio-
vascular risk such as tumor necrosis factor-α,
homocystein, and plasminogen activator inhibitor-1 are
increased in women with PCOS [26-28]. Several large-
scale prospective studies have shown that CRP is a strong
independent predictor of future CVD and/or stroke
[12,29]; however, only a few studies have determined CRP
levels in women with PCOS. Kelly et al. [13] reported that
women with PCOS have significantly increased CRP
concentrations compared with women who demonstrate
normal menstrual cycles and normal androgen levels. In
contrast, Mohlig et al. [15] did not observe these same
findings in women with PCOS.  
In the present study, hsCRP concentrations in the PCOS
group were higher than in the control group; however,
this effect disappeared after adjusting for BMI. In
women with PCOS, hsCRP levels were correlated with
CVD risk factors such as waist circumference, BMI, VFA,
systolic and diastolic blood pressures, and IMGU.
Multiple regression analysis showed that BMI, systolic
blood pressure, and IMGU predicted increased hsCRP
levels in PCOS women.
As previously reported, it appears that obesity is a major
factor associated with elevated CRP in individuals with
metabolic syndrome [30]. Moreover, visceral fat correlates
with CRP concentrations independently of total adiposity
[31].  
Hyperandrogenemia in PCOS can alter body fat
distribution and result in central obesity, which may affect
insulin sensitivity in women. We did not observe any
association between hsCRP and free testosterone levels
after adjusting for BMI, blood pressure, and IMGU.
Therefore, it seems unlikely that hyperandrogenemia
is linked to chronic inflammation in women with PCOS.
These results are consistent with previous studies that
showed no correlation between testosterone and CRP
levels after adjusting for VFA [13,15]. Therefore, further
studies are required to identify potential mechanisms
underlying the relationship between CRP and testosterone
concentrations in women with PCOS.
In this study, CRP levels in women with PCOS were
lower than in previous reports [13-15]. Boulman et al. [14]
reported that PCOS women with CRP concentrations
greater than 3 mg/L had a higher prevalence of moderate
cardiovascular risk compared with BMI-matched controls.
hsCRP levels in the PCOS women in our study were below
this level (0.72±0.20 mg/L). Albert et al. [32] reported
that the distribution of CRP levels varied significantly by
ethnic group. In this study, Asian women showed lower
CRP levels as compared with Caucasian and Hispanic
women. This may partially explain the relatively low CRP
levels in our subjects. Moreover, the women with PCOS
who participated in our study were quite young (17-35
years) and may have a relatively smaller risk of CVD
compared with other studies. Collectively, these factors
appear to contribute to the low CRP levels observed in this
study. Therefore, age, BMI and gender should be con-354 The Korean Journal of Internal Medicine Vol. 24, No. 4, December 2009
sideredwhen interpreting CRP data [33,34]. 
In conclusion, our study showed that PCOS is not
associated with increased CRP levels, but rather, docu-
mented risk factors for CVD such as BMI, blood pressure,
and insulin sensitivity predict CRP levels in PCOS.
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